Biotech Industry Examiner’s Post

In case you missed it, SelSym Biotech is in the news! https://lnkd.in/gspH8Tae SelSym's co-founder (and founding CEO) Ashley Brown led a multi-university, multi-investigator team that included her fellow co-founders, Seema Nandi, Ph.D. (current CEO), Andrew Lyon (CSO), and Tom Barker (President), our Director of Translational Clinical Development, Kimberly Nellenbach, PhD., and one of our trusted clinical advisors Maureane Hoffman on a major project that clearly shows the efficacy and safety of platelet-like particles in a range of animal models. Furthermore, this work illustrates the ability of these particles to clear from circulation via renal excretion, which makes the innovation potentially transformative in the world of injectable bio-nanomaterials. For more information on this remarkable advancement, check out the original article in Science Translational Medicine: https://lnkd.in/gX9TRmt7 #hemostasis #trauma #regenerativemedicine #woundhealing #platelets

Here's a quick roundup of some recent funding rounds in the UK's biotech sector so far this week... 🔬 Nuclera secured a significant $57M Series C round to advance its gene and protein synthesis technology, driving progress in synthetic biology. https://lnkd.in/evrUFCPt 🤖 Antiverse, based in Cardiff, raised €4.2M to leverage generative AI for antibody design, pointing to the growing role of AI in life sciences. https://lnkd.in/etE_J3AX 🧬 Shift Bioscience closed a $12.5M seed round to develop anti-aging therapeutics, a space that continues to garner intense interest and investment. https://lnkd.in/eUmDKdDH 🌍 Eli Lilly has committed $364M towards addressing the obesity crisis through UK-based research, further emphasizing the global interest in healthcare solutions. https://lnkd.in/eAeBpQDd 🧫 CellRev, based in Newcastle, secured a £14M investment to scale up its work in cellular regeneration technologies. https://lnkd.in/eAJxR7Y8 These investments reflect a broader trend of robust VC interest in health tech and life sciences, particularly as Q3 saw notable venture capital inflows. https://lnkd.in/ebvXNwxy What’s exciting is not just the scale of these investments for biotech innovation, but the strategic focus on technologies that promise to tackle some of the biggest health challenges we face today. #Biotech #LifeSciences #HealthTech #Investment #Innovation #VentureCapital #SyntheticBiology #GenerativeAI #Healthcare #AntiAging #UKBiotech

#CA-based S2 Genomics secures $16million in series A Round #funding from BroadOak Capital Partners and Research Corporation Technologies (RCT). The funding will help S2 Genomics accelerate #commercial adoption of its benchtop Singulator platform, which utilizes single-use cartridges to enable reproducible, rapid, and automated tissue #dissociations into single cell or nuclei suspensions, as per reported by businesswire.com. Customers use suspensions of nuclei and high-viability cells produced by the Singulator to advance #neuroscience and #oncology research. Since its first commercial launch in 2020, Singulator has been adopted globally by leading academic research #organizations, #pharmaceutical companies, biotech companies and service providers. S2 Genomics is a global life science tools company based in Livermore, California. Their proprietary Singulator platform automates the #preparation of single cell and single nuclei #suspensions from solid tissues for single cell genomics applications, enabling single cell biology for every scientist. S2 Genomics BroadOak Capital Partners Research Corporation Technologies, Inc. Jonathan Schimmel To share your startup story write us on - contact@startuprise.io #s2genomics #funding #startup

Cureline Baltic is proud to announce the initiation of “Implementation of Mission-based Science and Innovation Programs” Project! The project aims at the execution of three mission themes, whereby Cureline Baltics participates as a member of Vilnius University’s consortium, implementing the “Innovations for Health” theme. The “Innovations for Health” mission is inclusive of 7 mission-driven R&D projects, one of which is the prime focus of Cureline Baltic, ONCOINTEGRA. ONCOINTEGRA is a drive for the development of a clinical multi-omics platform for oncology diagnostics and advanced therapeutics. The project is financed by the Economic Recovery and Resilience Plan "Next Generation Lithuania" and the State Budget of the Republic of Lithuania, being valued at €94.728 million, with a funding totaling at €88.530 million. To learn more about the project, visit: https://shorturl.at/hclEY #NextGenerationEU #BendraiFinansuojaEuroposSąjunga #MESkuriamES #InvesticijuPrograma #ESinvesticijos

Big congratulations to S2 Genomics, a pioneering force in the realm of tissue sample preparation systems for single cell genomics assays, proudly announced today the successful closure of its Series A funding round, securing an impressive $16 million. This significant milestone was achieved through the strategic backing of leading investment entities, BroadOak Capital Partners and Research Corporation Technologies, Inc. The infusion of funds is poised to catapult S2 Genomics into a new phase of growth by expediting the widespread adoption of its innovative Singulator platform. Positioned as a benchtop solution, the Singulator leverages single-use cartridges to execute reproducible, swift, and automated tissue dissociations, generating single cell or nuclei suspensions. These suspensions, comprised of nuclei and high-viability cells, prove instrumental in advancing research within the realms of neuroscience and oncology. Jonathan Schimmel, President and CEO of S2 Genomics, expressed gratitude for the overwhelming positive response from customers utilizing the Singulator platform. He emphasized the pivotal role the additional funding will play in expanding their customer base and diversifying applications for the Singulator platform. Schimmel acknowledged the valuable contributions of BroadOak and RCT, citing their wealth of knowledge and experience in the field as a crucial asset in steering the company's next phase of growth. Anup Parikh, Operating Partner of BroadOak Capital Partners, shared the excitement of partnering with S2 Genomics and its accomplished team under Jonathan Schimmel's leadership. Parikh highlighted the Singulator platform's ability to address scalability challenges in single cell genomics, making it more accessible for new customers to delve into single cell applications. Since its initial commercial launch in 2020, the Singulator platform has garnered global adoption by prestigious academic research organizations, pharmaceutical companies, biotech firms, and service providers. Comprising an easy-to-use benchtop instrument, single-use consumables, and an expanding repertoire of over 80 validated protocols for single cell or single nuclei sample preparation, the Singulator platform stands out for its reproducibility and precision. By eliminating a significant bottleneck in single cell genomics research, it empowers scientists to process more samples, thus advancing the frontier of single cell genomic applications. S2 Genomics looks forward to a promising future with the continued support of its investors and the broader scientific community. #funding #genomics #innovation #scientificadvancements #singlecell

🌟 Exciting News in Drug Discovery! 🌟 Thrilled to share the publication of groundbreaking research titled "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models" in Nature Biotechnology by Alex Zhavoronkov and the team at Insilico Medicine! 🔬 Leveraging cutting-edge AI technology, Alex Zhavoronkov and the Insilico Medicine team identified and TNIK as a promising anti-fibrotic target, paving the way for innovative therapeutic interventions. Key highlights: 1️⃣ Utilization of AI to discover TNIK as an anti-fibrotic target. 2️⃣ "Hallmarks of aging assessment" revealed promising results for TNIK. 3️⃣ Innovative molecule design using Chemistry42 AI for enhanced safety and efficacy. 4️⃣ Extensive in vitro and in vivo experiments leading preclinical candidates for lung and kidney fibrosis. 5️⃣ Successful completion of a clinical safety trial in humans. Excitingly, the paper is easily accessible for questions through the chat feature at https://lnkd.in/gzm3FaMW, and a comprehensive data repository is available at https://lnkd.in/gudR2pZN. 🌐 Explore recent publications and collaborations by Alex and Insilico, and dive into the therapeutic pipeline propelled by generative platforms. Read the full paper here: https://lnkd.in/epYVmPgf #Biotechnology #Innovation #AI #FibrosisResearch #TherapeuticDevelopment #NatureBiotechnology #ResearchBreakthroughs

We're really excited to announce that life science businesses based at Alderley Park secured almost £50 million in new R&D-linked funding in 2023. It was quite the year for the world leading science and tech campus as 2023 also saw an additional 95,000 sq ft of lab and office workspace let to new and existing customers. The funding supports major projects relating to cancer and brain tumour treatment as well as gene editing technology. 💡 Recognised as a Top 10 UK Venture Seed Deals by the BioIndustry Association (BIA)’s UK BioTech Financing Report 2023, Alderley Park-based Pencil Biosciences Limited attracted £5.6 million in seed funding for its novel gene modulation technology and aims to transform the gene-editing landscape for use in therapeutics and industrial biotechnology. 💡 Meanwhile, biomolecular medicine specialists, Sutura Therapeutics Ltd raised £7.8m, also featured in the top 10, while other companies who successfully raised investment at the Park include medical device start-up, QV Bioelectronics, Nodus Oncology and clinical-stage biotech company Redx Pharma, whose share issue generated £14m in investment. ICYMI, 2024 marks the 10 year anniversary of Bruntwood acquiring the Park - we can’t wait to see what exciting R&D and funding opportunities arise this year! Read more here: https://bit.ly/484b0Ta #ResearchFunding #CustomerSuccess #IndustryReport #BioTech

Industry updates: Multiomics & Precision Medicine 👇 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: 🤑 CytoReason, an AI medical tech firm, has secured $80 million. They’re setting up shop in Cambridge, MA later this year! 💵 Predicta Biosciences, a precision oncology company, raised $5.2 million to expand their team, build a CLIA lab, and develop GenoPredicta. 💶 Integra Therapeutics, a biotech specialising in gene writing tools has raised €10.5 million to support its FiCAT platform for advanced therapies. 𝗦𝗲𝗾𝗦𝗲𝗰𝗿𝗲𝘁𝘀: ❤️ Guardant Health faces a $900K payout to settle claims of false lab test submissions. 💚 QIAGEN is making tough decisions, laying off 175 employees and shutting down their NeuMoDx site in Michigan. :( 💛 Good news for Bruker as the injunction halting NanoString Technologies, Inc. CosMx Spatial Molecular Imager in Germany has been lifted. 💜 Thermo Fisher Scientific has successfully acquired Olink Proteomics. 🧡 Metabolon, Inc. has expanded its library to include 70 pesticides. 🖤 Inocras Inc. and Watchmaker Genomics are teaming up to enhance genomic research and clinical applications. ❤️ Genomics plc and Vertex Pharmaceuticals have extended their partnership. They're using human genetics and ML to improve the discovery / development of new precision medicines. #Forestomics

#News: Arena BioWorks a newly launched #biomedical #researchinstitute, has set its sights on accelerating the translation of basic #biologicalresearch into new #biotechtherapeutics. While its focus is not exclusively on longevity, the institute says it aims to address a broad range of indications, with “aging” and “brain health” specifically mentioned. Arena is backed by several billionaires, with Michael Dell, Jim Breyer, Michael Chambers and Elisabeth DeLuca revealed as founding investors. The New York Times has reported that the institute is bankrolled to the tune of $500 million. Co-founded by Harvard University scientist Stuart Schreiber, former Bain Capital Co-Chair Steve Pagliuca, and Tom Cahill of Newpath Partners, the institute operates under a unique, privately funded model that it hopes will attract top scientists to join its team. The institute claims its private funding model empowers scientists to investigate any disease without the constraints of grant funding or venture capital approval. “Arena’s single source of funding frees our scientists from the typical short-term cycles of grant and venture capital funding,” said Schreiber. “Our aim is to accelerate progression from deep mechanistic human biology to biotech-enabled drug development.” Located in the Kendall Square biotech hub in Cambridge, MA, Arena’s core scientific team includes #CRISPR #geneediting innovator Keith Joung and other yet-to-be-announced scientists. “Arena’s approach to drug discovery, which hinges on strong basic science and relevant human biology, appeals to me as a physician-scientist,” said Joung. “With an experiment that directly probes human biology, we can immediately consider how to answer fundamental questions in the most physiologically relevant way, which also puts us that much closer to translating the answer into a drug.” Inspired by the success of #BellLabs, Arena says it aims to create for-profit #biotechnology companies alongside its core research mission. The institute will integrate discovery and company creation under one roof, relying solely on private funding to translate insights into discoveries, leveraging platform technologies including proteomics, protein and antibody engineering, and gene and epigenetic editing, among others. Read more from Longevity.Technology using the link in the comments.

🔬 Unlock the Future of Biotech and Genomics with Premium Domain Investments 🔬 🌟 Position your company at the forefront of the biotech and genomics revolution 🌟 We offer a rare portfolio of exclusive, high-value domains catering to biotech, genomics, and omics innovators. Whether advancing research, developing breakthrough therapies, or building the next big biotech startup, these domains provide a strategic edge in a rapidly growing industry. https://lnkd.in/exdBeE79 https://lnkd.in/e72jvg_w https://lnkd.in/eN3KpDTn https://lnkd.in/ewGUKPbc https://lnkd.in/eVQ8HaWu 🌐 Featured Domains: CDKQ.us | CDKQ.org | CDKQ.ai – Ideal for companies leveraging AI and cutting-edge genomics research. CDK.ing – A top-tier domain for organizations driving innovation in biotechnology. BarrierBreak.ing – Perfect for pioneers breaking new ground in biotech and scientific research. UpOmics.com – Designed for the future of omics technologies and data-driven scientific breakthroughs. OmicsZone.com – Tailored for businesses leading the charge in omics and genomics solutions. Why Invest in These Domains? Strong Branding: Position yourself as a leader in biotech and genomics with memorable, future-oriented domains. Competitive Advantage: Gain an edge in an industry that is seeing explosive growth in research and innovation. Future-Proof Your Business: These domains are aligned with the emerging fields of genomics, biotech, and personalized medicine, ensuring long-term relevance. Rare Opportunity: Domain names like these are in high demand and exclusively available to forward-thinking biotech companies. 🚀 Transform your biotech business with a powerful domain name. These premium domains are your key to establishing authority and leading next-gen biotech and omics research. Don’t miss out—secure them now before your competition does! Contact us today to discuss acquisition options and pricing. #biotech #genomics #omics #domaininvestment #biotechstartups #research #innovation #personalizedmedicine